Skip to main content

Thomas McNaughton, John Lewis Join Zyomyx; Richard Pops Elected BIO Chairman; Klaus Pohle Nominated to Lion Board; and Others

NEW YORK, June 25 - Thomas McNaughton has been appointed vice president of Intellectual Property, and John Lewis has joined as vice president of sales and marketing, at Zyomyx, the company said today.


McNaughton joins the Hayward, Calif., protein biochip company from Aclara Biosciences, where he was vice president of legal affairs. He also has served as vice president of intellectual property at Acuson and worked as senior counsel for Chevron; senior director of business development and licensing counsel for Genelabs; and senior patent counsel for Syntex.


Lewis previously was vice president of customer development at Becton Dickinson subsidiary BD Biosciences Clontech. Prior to that, he was director of product sales at Celera Genomics.


The appointment of McNaughton and Lewis follows Robert Monaghan's arrival earlier this month as CEO of the company.


With Lewis' arrival, Hirday Bhathal,  Zyomyx's vice president of corporate development, will leave the company.

Richard Pops was elected chairman of the Biotechnology Industry Organization's board of directors at the BIO 2003 Annual Convention in Washington, D.C. June 24.


Pops is CEO of Alkermes, a Cambridge, Mass.-based biopharmaceutical company. He succeeds David Robinson, chairman and CEO of Ligand Pharmaceuticals, in a two-year term.

CEO of Ligand Pharmaceuticals, as chair of BIO.


Bijan Almassian has been appointed Chief Operating Officer of Panacea Pharmaceuticals, the Gaithersburg, Md., company said June 24.


Almassian comes to Panacea, a genomics- and proteomics-based diagnostics and therapeutics company, from AlexiaPharma, a pain and obesity therapeutics developer based in New Haven, Conn., where he served as president and COO.  Almassian has held previous management positions at Vion Pharmaceuticals, GeneLabs, Genzyme/Integrated Genetics, Instrumentation Laboratories, and Orion Research.


Aileen Alvarado-Swaisgood has been appointed Western Regional Sales Manager of Nonlinear Dynamics' US subsidiary, Nonlinear USA., the company said June 24.


Aileen joins the UK-based life sciences informatics firm from Accelrys, where she worked in sales management most recently covering Latin America and the US and Canadian governments.

Klaus Pohle has been appointed to the supervisory board of Lion Biosciences, the company announced June 24.

Pohl was CFO of Schering from 1981 through April of this year. In 1989, he was named deputy CEO of the company. He currently serves on the supervisory boars of DWS Investment GmbH and Coty. He is also a professor of business administration at the Technical University of Berlin.

Lion will formally nominate Pohl at its annual meeting August 7, at which it plans to reduce the supervisory board from six to three members. The other members on the new, smaller slate include Chairman Juergen Dorman, and Richard Roy, a former Microsoft executive.


Richard De Schutter has been elected Chairman of Incyte's board of directors, the Palo Alto, Calif. company said June 23.


De Schutter, who has served on Incyte's board since January 2002, was chairman and CEO of DuPont Pharmaceuticals from January to October 2001. Prior to holding the DuPont position, De Schutter was vice-chairman, chief administrative officer and a director at Monsanto, after Monsanto acquired Searle, where De Schutter had been chairman and CEO.


Currently De Schutter also serves on the boards of Smith & Nephew, General Binding, and Varian.



The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.